Shire PLC

Latest Shire PLC News and Updates

  • uploads///Travis Perkins versus Wolseley
    Macroeconomic Analysis

    Travis Perkins Rebounded, Led EWU by 5.09%

    Travis Perkins was at the top of the iShares MSCI United Kingdom ETF on October 23, 2015, as analysts showed positivity toward the construction industry.

    By Renee Blakely
  • uploads///INTC
    Fund Managers

    AQR Capital increases stake in Intel

    Intel generated ~$5.7 billion in cash from operations. The company paid quarterly dividends of $1.1 billion and repurchased 122 million shares for $4.2 billion.

    By Diana Key
  • uploads///MNK
    Fund Managers

    Adage Capital adds a new position in Mallinckrodt

    Adage Capital added a new position in Mallinckrodt Plc (MNK) in the third quarter of 2014. The position accounted for 0.82% of the fund’s total portfolio.

    By Samantha Nielson
  • uploads///PE and share price
    Company & Industry Overviews

    Pfizer’s Medivation Acquisition: What You Need to Know

    On August 22, Medivation (MDVN) and Pfizer (PFE) entered into a definitive agreement. Pfizer will acquire Medivation for a consideration of ~$14 billion.

    By Jillian Dabney
  • uploads///AAL
    Consumer

    American Airlines gets significantly lower position in Appaloosa

    Appaloosa Management significantly lowered its position in American Airlines (AAL) in the third quarter that ended in September 2014. The position accounts for 3.81% of the fund’s total third-quarter portfolio.

    By Samantha Nielson
  • uploads///krystexxa
    Company & Industry Overviews

    Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug

    Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.

    By Jillian Dabney
  • uploads///BYI
    Fund Managers

    AQR Capital initiated position in Bally Technologies Inc.

    AQR Capital initiated a position in Bally Technologies during the third quarter of 2014 that accounts for 0.22% of the fund’s 3Q14 portfolio.

    By Diana Key
  • uploads///horizon as orphan drug company
    Company & Industry Overviews

    Buy Allows Horizon to Further Expand into Orphan Drug Space

    Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.

    By Jillian Dabney
  • uploads///Graph Autosomal recessive pattern
    Company & Industry Overviews

    BioMarin Leads in the Market for Mucopolysaccharidoses Disorders

    BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.

    By Jillian Dabney
  • uploads///Global Technology IPOs
    Company & Industry Overviews

    What Bob Doll Thinks about the IPO Market in 2017

    Equity market indexes across the United States are surging and recording all-time highs. The volatility index is also falling, which could be a good sign for IPO activity in 2017.

    By Mary Sadler
  • uploads///Strensiq
    Earnings Report

    How Alexion Plans to Fuel Strensiq Sales

    With the Enobia acquisition in February 2012, Alexion benefited in long-term disease awareness, diagnostic planning, and initiatives in the HPP space.

    By Jillian Dabney
  • uploads///lyrica
    Company & Industry Overviews

    Lyrica to Lose Patent Protection in the US in 2018

    After Pfizer lost patent protection for Lipitor, Lyrica became increasingly important to it. During its peak in 2014, Lyrica added $5.2 billion to Pfizer’s top line.

    By Jillian Dabney
  • uploads///SHPG
    Fund Managers

    Shire Gets Dropped from AQR Capital’s Portfolio

    During the fourth quarter of 2014, AQR Capital closed its position in Shire plc (SHPG). The fund sold its entire stake of 816,116 shares in the company.

    By Stuart McKenzie
  • uploads///Portfolio Breakdown of the FHJUX
    Fund Managers

    Sector Composition Changes in FHJUX until 1Q16

    FHJUX’s assets were spread across 73 holdings as of March 2016, which is six less than a quarter ago. It was managing assets worth $1.3 billion as of the end of March.

    By David Ashworth
  • uploads///NXPI
    Financials

    NXP Semiconductors is Appaloosa Management’s new position

    Appaloosa Management initiated a new position in NXP Semiconductors NV (NXPI) in the third quarter that ended in September 2014. The position accounts for 2.55% of the fund’s total third-quarter portfolio.

    By Samantha Nielson
  • uploads///Adage
    Financials

    A key overview of Adage Capital’s holdings in 3Q14

    Adage Capital’s US long portfolio grew from $38.69 billion in 2Q14 to $40.2 billion in 3Q14. The portfolio comprised around 699 stocks.

    By Samantha Nielson
  • uploads///KMI
    Energy & Utilities

    Kinder Morgan’s position with Adage Capital eliminated

    Adage Capital exited a position in Kinder Morgan Inc (KMI) in the third quarter. The position accounted for 0.37% of the fund’s total 2Q portfolio.

    By Samantha Nielson
  • uploads///C
    Financials

    Citigroup gets raised position with Adage Capital

    Adage Capital raised its position in Citigroup Inc. (C) in the third quarter. The position accounted for 0.98% of the fund’s total 3Q portfolio.

    By Samantha Nielson
  • uploads///NI
    Energy & Utilities

    Adage Capital raises its position in NiSource

    Adage Capital raised its position in NiSource Inc. (NI) in the third quarter. The position accounted for 0.52% of the fund’s total 3Q14 portfolio.

    By Samantha Nielson
  • uploads///WHR
    Consumer

    Whirlpool’s position upped in Appaloosa Management

    Appaloosa Management upped its position in Whirlpool Corporation (WHR) in the third quarter that ended in September 2014. The position accounts for 4.29% of the fund’s total third-quarter portfolio.

    By Samantha Nielson
  • uploads///EXPE
    Consumer

    Appaloosa exits position in Expedia

    Appaloosa Management exited a position in Expedia, Inc (EXPE) in the third quarter that ended in September 2014. The position accounted for 0.99% of the fund’s total portfolio in the second quarter.

    By Samantha Nielson
  • uploads///Xyrem
    Company & Industry Overviews

    Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?

    Jazz Pharmaceuticals’ Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Recommendations for Shire as of October 30

    Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Shire: Why Analysts Expect Revenue Growth in Q3 2018

    Analysts are expecting Shire (SHPG) to report a 3.3% growth in revenue when it reports its third-quarter earnings on November 1.

    By Mike Benson
  • uploads///analysis _
    Earnings Report

    What to Expect from Thermo Fisher’s Third-Quarter Earnings

    Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GW Pharmaceuticals: Recommendations and Market Capitalization

    Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis ADR’s Performance and Revenue Estimates for Q3 2018

    Novartis’s (NVS) stock price has increased ~14.3% in the third quarter, and its stock rose ~2.8% year-to-date on October 2.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Shire’s Quarterly Revenue Trend

    Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    A Look at Shire’s Valuation on September 19

    Shire reported adjusted EPS of $3.88 on revenue of ~$3.9 billion in the second quarter, a 4.6% YoY (year-over-year) rise.

    By Mike Benson
  • uploads///thermometer _
    Earnings Report

    Shire’s Q2 2018 Earnings Beat Analyst Estimates

    Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What to Expect from Shire’s Q2 2018 Earnings on July 31

    Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.

    By Mike Benson
  • uploads///addiction _
    Earnings Report

    How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?

    BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.

    By Daniel Collins
  • uploads///Shire
    Miscellaneous

    Takeda Pharmaceutical Makes 4th Successive Bid for Shire

    Takeda Pharmaceutical’s (TKPYY) bid for Shire (SHPG) has piqued a lot of investor interest.

    By Kenneth Smith
  • uploads///blood __
    Company & Industry Overviews

    No Bid Coming for Shire Reportedly

    Will Allergan buy Shire? – Apparently not CNBC saying no bid is likely.  Allergan is off its lows – only down $5 now and Shire is back to flat after being up as much as $15 (~10%) earlier. From earlier: Shire PLC (NASDAQ: SHPG) is up 4.5% as of 11:10 A.M. on Thursday following an announcement […]

    By JP Gravitt
  • uploads///FD
    Company & Industry Overviews

    Alexion Pharmaceuticals in 4Q17 and Fiscal 2017

    In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Eloctate
    Company & Industry Overviews

    How Is Bioverativ’s Eloctate Positioned Now?

    In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Hemlibra
    Company & Industry Overviews

    How Is Roche’s Hemlibra Positioned for 2018?

    Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.

    By Daniel Collins
  • uploads///hemophilia
    Company & Industry Overviews

    How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17

    In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.

    By Daniel Collins
  • uploads///Part  VNTR
    Materials

    Venator to Participate in Food Ingredients Europe

    Venator, a spin-off of Huntsman (HUN), rose 0.80% and closed at $23.28 for the week ending November 24, 2017. The stock was listed on August 3, 2017.

    By Peter Neil
  • uploads///Alprolix Eloctate
    Company & Industry Overviews

    How Are Bioverativ’s Key Drugs Positioned after 2Q17?

    In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Erwinaze Sales May Remain Flat in 2017

    Erwinaze saw net sales worth $49 million in 2Q17, almost flat compared to the drug’s revenues of $50 million in 2Q16.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ’s Research Pipeline May Boost Future Revenues

    Bioverativ (BIVV) plans to improve compliance rates for hemophilia patients further by launching therapies with lower dosage frequency.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ’s Eloctate Sees More Demand from Hemophilia A Patients

    In 1Q17, Bioverativ’s Eloctate witnessed revenues close to $155.9 million, which is about $48.0 million more YoY (year-over-year).

    By Margaret Patrick
  • uploads///Global Technology IPOs
    Macroeconomic Analysis

    Why More Companies Want to Stay Private

    The equity markets across the US (SPY) (QQQ) are surging with indexes recording all-time highs in 2017.

    By Mary Sadler
  • uploads///salix portfolio
    Company & Industry Overviews

    Valeant’s Salix Acquisition Saga

    Valeant won the acquisition race for Salix by valuing it at $14.5 billion, inclusive of net debt. In April 2015, Valeant paid $158 per Salix share.

    By Jillian Dabney
  • uploads///Portfolio Breakdown of the FHJUX
    Fund Managers

    Looking at the Portfolio of the Fidelity Advisor Europe Fund

    Industrials and financials are the top two invested sectors of FHJUX, and each sector commands more than one-fifth of the portfolio.

    By David Ashworth
  • uploads///Chart
    Earnings Report

    Eli Lilly and Co.’s 3Q16 Estimates: Neuroscience Franchise

    Another franchise from Eli Lilly and Co.’s (LLY) human pharmaceuticals segment is the neuroscience franchise.

    By Mike Benson
  • uploads///sovaldi patients
    Company & Industry Overviews

    How Gilead Dominates the HCV Space

    In January 2012, Gilead Sciences (GILD) acquired Pharmasset and got access to sofosbuvir. In December 2013, the FDA approved sofosbuvir under the brand name Sovaldi.

    By Jillian Dabney
  • uploads///hemophilia revenue
    Company & Industry Overviews

    Why Are Revenues from Pfizer’s Rare Disease Portfolio Falling?

    BeneFIX, the major contributor to Pfizer’s (PFE) Rare Disease portfolio, is indicated for hemophilia B. During the first six months, the drug earned $367 million.

    By Jillian Dabney
  • uploads///lyrica
    Company & Industry Overviews

    How Pfizer’s Internal Medicine Core Drugs Are Performing

    The major contributors in Pfizer’s (PFE) Internal Medicine business include Lyrica and Viagra. Lyrica’s Innovative Health (or IH) contribution to the Internal Medicine portfolio stood at 48%.

    By Jillian Dabney
  • uploads///soliris opportunity
    Earnings Report

    How Significant Is Alexion’s Opportunity with Soliris?

    Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.

    By Jillian Dabney
  • uploads///LSD portfolio
    Earnings Report

    How Will Shire’s LSD Portfolio Perform in 2016?

    Shire’s (SHPG) LSD (or lysosomal storage disorders) portfolio consists of Elaprase, Replagal, and Vpriv.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Inside Lilly’s 2Q16 Estimates for Its Neuroscience Franchise

    Another franchise in Eli Lilly’s Human Pharmaceuticals segment is the neuroscience franchise, which contributes ~13% of Lilly’s total revenues.

    By Mike Benson
  • uploads///dupilumab
    Earnings Report

    Regeneron’s Dupilumab: How Much Potential Does It Hold?

    Dupilumab has a breakthrough therapy designation from the FDA for the indication of moderate-to-severe atopic dermatitis in adults.

    By Jillian Dabney
  • uploads///ev to ebitda
    Company & Industry Overviews

    The Truth behind Horizon’s EV-to-EBITDA Performance

    On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    BioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%

    As of June 1, 2016, BioMarin Pharmaceutical (BMRN) was the most underperforming stock among the large-cap stocks of the SPDR S&P Biotech ETF (XBI).

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Shire’s Shareholders Approve Baxalta Merger: What’s Next?

    Shire (SHPG) performed the worst among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) on May 27, 2016.

    By Peter Neil
  • Company & Industry Overviews

    Timely Energy Exposure Helped FHJUX in 1Q16

    The Fidelity Advisor Europe Fund – Class A (FHJUX) fell 1.8% in 1Q16. But it still emerged as an above-average performer among the 12 funds in this review.

    By David Ashworth
  • uploads///angioedema
    Company & Industry Overviews

    How Does Shire Lead the Angioedema Space?

    Cinryze and Firazyr are Shire’s (SHPG) two drugs in its hereditary angioedema portfolio. Together, these two drugs crossed $1 billion in sales in fiscal 2015.

    By Jillian Dabney
  • uploads///Share price after shire baxalta deal
    Company & Industry Overviews

    The Shire-Baxalta Merger: A Look at the Details

    Following news of the Shire-Baxalta merger, Baxalta’s share price rose and Shire’s share price fell.

    By Jillian Dabney
  • uploads///VOD
    Company & Industry Overviews

    Defitelio: Volume and Pricing Challenges

    Jazz Pharmaceuticals’ Defitelio is the first and only approved treatment that increases survival in VOD patients with multi-organ dysfunction (or MOD).

    By Jillian Dabney
  • uploads///vyvanse
    Company & Industry Overviews

    What’s Happening with a Generic Version of Vyvanse?

    Vyvanse, Shire’s (SHPH) key drug, earned $1.7 billion in 2015, a 21% annual growth. Analysts expect Vyvanse to add $1.9 billion and $2.1 billion to Shire’s top line in 2016 and 2017.

    By Jillian Dabney
  • uploads///ADHD portfolio
    Company & Industry Overviews

    How Vyvanse Could Fuel Shire’s ADHD Portfolio Sales

    Vyvanse is Shire’s leading ADHD drug, constituting 80% of the company’s ADHD portfolio. In fiscal 2015, Vyvanse earned the company $1.7 billion.

    By Jillian Dabney
  • uploads///ANR
    Company & Industry Overviews

    Analysts Are Optimistic About Shire

    According to a Bloomberg consensus of 15 brokerage firms, 86.7% of analysts rated Shire a “buy,” and 13.3% rated it a “hold.” None issued a “sell” rating for the stock.

    By Jillian Dabney
  • uploads///Share price after shire baxalta deal
    Company & Industry Overviews

    Why Did Shire Fall after Shire-Baxalta Acquisition Announcement?

    On January 11, 2016, Shire (SHPG) announced a merger agreement with Baxalta for a whopping $32 billion. The Shire-Baxalta deal is still in progress and should close by mid-2016.

    By Jillian Dabney
  • uploads///PE
    Company & Industry Overviews

    Shire at Discount on Price-to-Earnings Basis: A Good Opportunity?

    With estimated double-digit sales growth and post-Baxalta-acquisition synergies, Shire’s PE could rise in the near term and result in a rise in share price.

    By Jillian Dabney
  • uploads///Natpara
    Company & Industry Overviews

    Shire’s Acquisition Gives It Natpara and Gattex

    Gattex is the first and only analog of glucagon-like peptide-2 (or GLP-2) indicated for short bowel syndrome. The drug is known as Gattex in the United States and Revestive in Europe.

    By Jillian Dabney
  • Company & Industry Overviews

    An Above-Average Year for FHJUX

    FHJUX’s quantitative metrics place it as an above-average performer for the one-year period ended March 15, 2016. This period covers two major stimulus announcements by the ECB.

    By David Ashworth
  • uploads///Orkambi revenue projections
    Earnings Report

    Orkambi: Recent Addition to the Vertex Portfolio

    In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for treating cystic fibrosis in the United States for patients 12 years and older with two copies of the F508del mutation.

    By Jillian Dabney
  • uploads///BXLT SHPG combination
    Miscellaneous

    The Baxalta–Shire merger: Basics of Shire Pharmaceuticals

    Shire is a biopharmaceutical company that focuses on rare diseases. Shire is best known for its treatments in ADHD, and the market here is quite large.

    By Brent Nyitray, CFA, MBA
  • uploads///Portfolio Breakdown of the FHJUX
    Macroeconomic Analysis

    How the Fidelity Advisor Europe Fund Allocated Its Portfolio in 2015

    The Fidelity Advisor Europe Fund was managing assets worth $1.4 billion as of the end of December.

    By David Ashworth
  • uploads///Analyst recommendations
    Earnings Report

    Vertex Pharmaceuticals: What Are Analysts’ Estimates?

    Vertex Pharmaceuticals will report earnings for 4Q15 and fiscal 2015 on January 27, 2016. The company’s major focus area is hereditary disorder cystic fibrosis (or CF).

    By Jillian Dabney
  • uploads///BXLT SHPG synergies
    Miscellaneous

    Growth and Synergies Drive the Baxalta–Shire Merger

    The Baxalta–Shire merger could create the top platform for rare diseases in the world. Baxalta brings Advate, a treatment for hemophilia, a rare blood disease.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph naglazyme
    Company & Industry Overviews

    Naglazyme: One of the Costliest Drugs in the United States

    The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.

    By Jillian Dabney
  • uploads///Vanguard  Index Fund Investor Class VFINX
    Company & Industry Overviews

    US Stock Indexes Fell in December amid Falling Oil Prices

    Let’s see why US stock indexes fell. The three US equity indexes that we review in this December recap series fell from November 30 to December 31, 2015.

    By Lynn Noah
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Celgene Falls on Profit Booking, IBB Large-Caps Fall by 0.5%

    Celgene (CELG) fell by 2.5% on December 28, 2015. The stock fell on profit booking after it closed at $122.07 on December 23, 2015.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    The SPDR S&P Biotech ETF Lingers in the Red as of December 3

    The SPDR S&P Biotech ETF (XBI) went down by 3.9% on December 3, which represents the third consecutive day of declines for the ETF. XBI closed at $68.91.

    By Peter Neil
  • uploads///Portfolio Composition FHJUX
    Macroeconomic Analysis

    The Fidelity Advisor Europe Fund: Class A (FHJUX)

    As of August 2015, the Fidelity Advisor Europe Fund was managing assets worth $1.45 billion. Founded in 1986, the fund’s net expense ratio is 1.35%.

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    Top Ten XBI Stocks by Market Cap Outperform August 25–31

    The top ten stocks of the SPDR S&P Biotech ETF (XBI) outperformed the top ten stocks of the iShares Nasdaq Biotechnology ETF (IBB) and the Health Care Select Sector SPDR ETF (XLV) for August 25–31.

    By Peter Neil
  • uploads///Graph Part
    Earnings Report

    How Does Vertex Compare to Its Peers?

    Though Vertex is trading close to the upper Bollinger Band, the stock doesn’t seem to be in the overbought position and is poised for long-term growth.

    By Peter Neil
  • uploads///Flextronics_Financial Snapshot
    Fund Managers

    AQR Capital Begins a Position in Flextronics International

    AQR Capital commenced a position in Flextronics International (FLEX). FLEX represented 0.3% of the fund’s 4Q14 portfolio.

    By Stuart McKenzie
  • uploads///AQR Capital_Top Holdings
    Fund Managers

    AQR Capital Trades Key Positions in its 4Q14 Portfolio

    The size of the AQR Capital Management’s portfolio was $48.2 billion in 4Q14, up from $36.4 billion in 3Q14.

    By Stuart McKenzie
  • uploads///MYL
    Fund Managers

    Paulson & Co. adds to its position in Mylan

    In July, Mylan said it would acquire Abbott Laboratories’ (ABT) non-US developed markets specialty and branded generics business.

    By Samantha Nielson
  • uploads///ABBV
    Fund Managers

    D.E. Shaw ups its position in AbbVie

    AbbVie develops and markets advanced therapies that address some of the world’s most complex and serious diseases.

    By Diana Key
  • uploads///CTSH
    Fund Managers

    Farallon Capital starts new position in Cognizant Tech Solutions

    During the third quarter, Farallon Capital Management initiated a position in Cognizant Technology Solutions (CTSH). The position accounted for 2.06% of the fund’s 3Q14 portfolio.

    By Diana Key
  • uploads///DUK
    Fund Managers

    Adage Capital adds stake in Duke Energy

    Adage Capital added a new position in Duke Energy in the third quarter. The position accounted for 0.20% of the fund’s total 3Q portfolio.

    By Samantha Nielson
  • uploads///TRW
    Fund Managers

    TRW Automotive Holdings is Adage Capital’s new position

    Adage Capital added a new position in TRW Automotive Holdings, which accounted for 0.32% of the fund’s total 3Q14 portfolio.

    By Samantha Nielson
  • uploads///RVBD
    Fund Managers

    AQR Capital sold its stake in Riverbed Technology

    On October 27, NetApp announced the acquisition of Riverbed’s SteelStore product line in an all-cash transaction for approximately $80 million.

    By Diana Key
  • uploads///AZN
    Fund Managers

    AQR Capital sold its position in AstraZeneca

    AstraZeneca is one of a few pure-play bio-pharmaceutical companies that span a medicine’s entire value chain.

    By Diana Key
  • uploads///GRT
    Fund Managers

    AQR Capital ups position in Glimcher Realty Trust

    Glimcher Realty Trust is one of the leading real estate investment trusts or REITs. It owns, manages, and develops a portfolio of retail properties.

    By Diana Key
  • uploads///GILD
    Fund Managers

    AQR Capital raises position in Gilead Sciences

    Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines for life-threatening illnesses around the world.

    By Diana Key
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.